Much like in the US, regulators in Europe are grappling with the safety of CBD, as it is already widely used among consumers.
The country is the first in the European Union to legalize cannabis possession and cultivation for non-medical purposes, with others expected to follow in 2022.
That is, “unless that legislation is appropriate for securing the attainment of the objective of protecting public health.”
Sativex and Epidyolex were approved for reimbursement by the NHS for some conditions. But health officials say product costs are too high, and benefits too low, for patients with chronic pain.
The report indicates that the National Institute for Health Research should prioritize research on cannabis-based products in five areas, including chronic pain in children and young people.